Clinical Trial

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 3, 2025 (before its estimated August 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-06-08; most recent amendment 2025-01-02.
Status change: Not Yet Recruiting → Recruiting 2022-08-28
Trial Details
NCT Number NCT05417321
Lead Sponsor Shanghai Huaota Biopharmaceutical Co., Ltd.
Conditions Advanced Solid Tumor, NSCLC
Enrollment 80 participants
Start Date 2022-08-25
Primary Completion 2025-08-01 (estimated)
Study Completion 2025-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-03